Nearly six months ago, PTC Therapeutics reported positive interim data for a drug in mid-stage development for Huntington’s disease, an inherited neurological disorder with limited treatment options ...
On Thursday, the FDA granted accelerated approval to PTC Therapeutics, Inc.’s (NASDAQ:PTCT) gene therapy for AADC deficiency, the first-ever gene therapy approved in the U.S. that is directly ...
WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics (PTCT), Inc. announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC ...
When the Human Genome Project concluded 21 years ago, it opened the door for genetic testing and a promise for lifesaving screenings and personalized medicine. An innovation that serves as a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results